<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma has informed the stock exchanges that it does not qualify as a 'Large Corporate' under SEBI's framework for the financial year ended March 31, 2025. As part of the annual disclosure, the company reported nil outstanding borrowings as of March 31, 2024, placing it below the threshold for large corporate classification. The company also disclosed its highest credit rating for the previous fiscal year as 'AA' from ICRA Limited. The filing is a routine SEBI compliance requirement for listed entities to confirm whether they fall under the large corporate category.
This is a routine regulatory disclosure with no material impact on shareholders. It signals that Natco Pharma carries virtually no debt and holds a strong AA credit rating, reflecting financial stability and low borrowing dependency.